Clinical results presented during the American Academy of Optometry (AAOPT) annual meeting offer new insights on real-world data from the CYPRESS study evaluating the safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses for slowing pediatric myopia progression.
Let’s start with this technology.
Developed by SightGlass Vision, Inc., a joint venture of CooperCompanies and EssilorLuxottica, as a proprietary, patent-protected lens technology, DOT is designed to focus on possibly slowing axial elongation and control / reduce myopia progression.
The technology’s acronym lends to its ability to integrate thousands of light-scattering elements—”dots”—that imitate more natural contrast at all distances before hitting the retina, according to the company.
And these lenses?
Designed to be used with SightGlass Vision’s DOT, the spectacles are intended to reduce contrast signaling within the retina and potentially slow myopia progression—leading to clear central vision with slightly less contrast in the lens’s peripheral component.
Talk about this CYPRESS trial.
The original Control of Myopia using Peripheral Diffusion Lenses: Efficacy and Safety Study (CYPRESS) trial (NCT03623074) was a 3-year, double-masked, randomized, multicenter, controlled study that enrolled 256 children (ages 6-10).
Participants were provided spectacles with one of two DOT lens designs (T1 or T2) or standard single-vision control lenses.
Didn’t we just hear about new data from CYPRESS?
We did (sort of)!
Four-year data was released as a follow-up to the study in September 2023 that demonstrated continued support of DOT spectacle lenses for pediatric myopia (read our coverage here).
And findings from the CYPRESS extension study released 42-month positive outcomes in April 2023 (coverage here).
Now to this new data … who’s presenting the findings?
Three optometrists and one researcher:
- Kylvin Ho, OD
- Ji Youn Kim, OD
- Kyleon Ho, OD
- Kellie Hogan
Gotcha. So tell me about the study.
Researchers reviewed clinical records from a Canadian-based independent practice to identify 39 pediatric patients (range 4-13 years; mean age = 8.02) who were prescribed DOT spectacle lenses as a monotherapy from October 2020 to December 2022.
The following measurements were recorded:
- Non-cycloplegic subjective refraction
- Snellen visual acuity (VA)
- Axial length (AL)
To note, all patients were of Asian ethnicity.
How long were they tracked?
Twelve-month (± 90 days) data was calculated for:
- Spherical equivalent refraction (SER)
- VA progression
- AL progression
First, what were the baseline numbers?
- Mean SER ± Standard deviation (SD)
- -2.50 ± 1.34 D (range -0.50 to -6.06 D)
- Mean AL
- 24.14 ± 0.96 mm (range 21.88 to 26.49 mm).
And the findings?
At 12 months:
- Mean SER progression (n = 39)
- -0.28 ± 0.32 D
- Mean AL progression (n = 36)
- 0.15 ± 0.17 mm
Give me specifics.
From the data readout, 56% of DOT-lens wearing patients, SER progression was limited to -0.25 D.
Further, VA was reported as 20/20 or better at each visit.
And compared to non-DOT lens-wearing patients?
Investigators used age-matched untreated myopic data from the Singapore Cohort Study of the Risk Factors for Myopia (SCORM) that predicted a mean annual AL of 0.39 mm.
Comparatively, DOT lenses decreased AL progression by 62% (0.24 mm).
Go on …
This data is similar to that of age-matched emmetropic eye growth (0.14 mm) predicted by the SCORM data, as well as the 12-month CYPRESS data (0.15 mm).
See here for details.
So what’s the big picture?
This real-world data indicates that the DOT lenses illustrated a decrease of myopia progression in clinical practice, suggesting results that are consistent with the previously-published CYPRESS trial clinical outcomes.
Lastly … any other related data presented at Academy?
As a matter of fact, yes!
SightGlass Vision has also sponsored two presentations:
- Control of Myopia using Diffusion Optics Technology Spectacle Lenses: 4-year Results (CYPRESS)
- presented by Debbie Laughton, PhD
- Visual Impact of Diffusion Optics Technology Lenses for Myopia Control
- presented by James Wolffsohn, BSc, MBA, PhD, of Aston University